Tekla Capital Management LLC Allogene Therapeutics, Inc. Transaction History

Tekla Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$25.79 - $39.02 $1.24 Million - $1.88 Million	-48,089 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$25.24 - $43.45 $1.21 Million - $2.09 Million	48,089 New	48,089 $1.21 Million
Q3 2020 Nov 13, 2020	SELL	$32.38 - $44.96 $7 Million - $9.71 Million	-216,069 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$18.39 - $54.04 $518,450 - $1.52 Million	-28,192 Reduced 11.54%	216,069 $9.25 Million
Q1 2020 May 14, 2020	BUY	$18.22 - $28.25 $2.99 Million - $4.63 Million	163,981 Added 204.26%	244,261 $4.75 Million
Q4 2019 Feb 13, 2020	BUY	$24.82 - $31.4 $1.99 Million - $2.52 Million	80,280 New	80,280 $2.09 Million

166

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $217M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.